- |||||||||| oxycodone controlled release / Generic mfg.
Trial completion, Phase classification: Early Use of Opioid in Radiation Mucositis (clinicaltrials.gov) - Jul 17, 2018 P2, N=200, Completed, Active, not recruiting --> Completed Not yet recruiting --> Completed | Phase classification: PN/A --> P2
- |||||||||| cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Trial completion, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jun 1, 2018 P1/2, N=3, Completed, N=500 --> 720 Active, not recruiting --> Completed
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Trial completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Feb 26, 2018 P2, N=24, Completed, Trial completion date: Apr 2018 --> Dec 2018 Active, not recruiting --> Completed | Trial completion date: Oct 2017 --> Oct 2017
- |||||||||| Inlyta (axitinib) / Pfizer
Trial completion, Trial primary completion date, Metastases: Nasopharyngeal Carcinoma (NPC) Axitinib (clinicaltrials.gov) - Apr 25, 2017 P2, N=37, Completed, Initiation date: Dec 2013 --> Jan 2017 Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2016
- |||||||||| Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
Trial completion, Phase classification, Enrollment change, Trial primary completion date: Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) - Apr 18, 2017 P1, N=28, Completed, Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Dec 2016 Active, not recruiting --> Completed | Phase classification: PN/A --> P1 | N=10 --> 28 | Trial primary completion date: Jun 2017 --> Jun 2015
- |||||||||| cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Mar 3, 2017 P1/2, N=3, Active, not recruiting, Active, not recruiting --> Completed | Trial primary completion date: Dec 2017 --> Mar 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| Inlyta (axitinib) / Pfizer
Trial primary completion date, Metastases: Nasopharyngeal Carcinoma (NPC) Axitinib (clinicaltrials.gov) - Jan 13, 2017 P2, N=37, Active, not recruiting, Trial primary completion date: Dec 2016 --> Mar 2017 Trial primary completion date: Dec 2016 --> Dec 2017
- |||||||||| MK-2206 / Merck (MSD)
Trial completion, Metastases: MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jan 13, 2017 P2, N=12, Completed, Trial primary completion date: Dec 2016 --> Dec 2017 Active, not recruiting --> Completed
- |||||||||| MK-2206 / Merck (MSD)
Enrollment change, Metastases: MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - Sep 30, 2016 P2, N=12, Active, not recruiting, Recruiting --> Completed | Trial primary completion date: Feb 2014 --> Mar 2012 N=45 --> 12
- |||||||||| Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
Trial primary completion date: Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) - Aug 11, 2016 P=N/A, N=10, Active, not recruiting, Recruiting --> Active, not recruiting Trial primary completion date: Jun 2016 --> Jun 2017
- |||||||||| cisplatin / Generic mfg., docetaxel / Generic mfg., sorafenib / Generic mfg.
Enrollment change, Trial primary completion date, Combination therapy, Metastases: Sorafenib Tosylate, Cisplatin, and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck (clinicaltrials.gov) - Jul 29, 2016 P1/2, N=3, Active, not recruiting, Trial primary completion date: Jun 2016 --> Jun 2017 N=41 --> 3 | Trial primary completion date: Mar 2017 --> Dec 2016
- |||||||||| Epstein-Barr Virus Specific Immunotherapy - Dana / Farber Cancer Institute
Trial primary completion date: Epstein-Barr Virus-Specific Immunotherapy for Nasopharyngeal Carcinoma (clinicaltrials.gov) - Mar 9, 2016 P=N/A, N=10, Active, not recruiting, Not yet recruiting --> Recruiting | Trial primary completion date: Jul 2015 --> Dec 2017 Trial primary completion date: Jan 2016 --> Jun 2016
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Enrollment change, Trial primary completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Mar 5, 2016 P2, N=24, Active, not recruiting, Trial primary completion date: Jan 2016 --> Jun 2016 Recruiting --> Active, not recruiting | N=43 --> 24 | Trial primary completion date: Feb 2016 --> Mar 2015
- |||||||||| MK-2206 / Merck (MSD)
Trial primary completion date, Metastases: MK-2206 in Recurrent Nasopharyngeal Carcinoma (clinicaltrials.gov) - Jan 30, 2016 P2, N=45, Active, not recruiting, Recruiting --> Active, not recruiting | N=36 --> 18 Trial primary completion date: May 2015 --> Dec 2016
- |||||||||| Inlyta (axitinib) / Pfizer
Enrollment closed, Trial primary completion date, Metastases: Nasopharyngeal Carcinoma (NPC) Axitinib (clinicaltrials.gov) - Jan 30, 2016 P2, N=37, Active, not recruiting, Trial primary completion date: Dec 2015 --> Dec 2017 Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2015 --> Dec 2016
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2015 P1, N=43, Completed, Recruiting --> Active, not recruiting | N=55 --> 36 Active, not recruiting --> Completed
- |||||||||| carboplatin / Generic mfg., docetaxel / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date: CADEN: Carboplatin and Docetaxel Followed by Epstein-Barr Virus Cytotoxic T Lymphocytes (clinicaltrials.gov) - Sep 9, 2015 P2, N=20, Completed, Recruiting --> Completed | Trial primary completion date: Dec 2015 --> Jul 2015 Active, not recruiting --> Completed | N=25 --> 20 | Trial primary completion date: Jan 2015 --> Jun 2014
- |||||||||| Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial primary completion date, Metastases: Carboplatin, Paclitaxel, Cetuximab, and Erlotinib Hydrochloride in Treating Patients With Metastatic or Recurrent Head and Neck Squamous Cell Cancer (clinicaltrials.gov) - Sep 8, 2015 P2, N=43, Recruiting, Active, not recruiting --> Completed | N=25 --> 20 | Trial primary completion date: Jan 2015 --> Jun 2014 Trial primary completion date: Feb 2015 --> Feb 2016
|